The University of MichiganNews & Information services
The University Record Online
search      Updated 11:59 AM February 10, 2003
 

front

accolades

news briefs

events

UM employment


obituaries
police beat
regents round-up
research reporter
letters


archives

Advertise with Record

contact us

contact us
 
 
LSI names external advisory board

The Life Sciences Institute (LSI) has named a 15-member external advisory board of leading figures from science and industry to guide its operations. The board includes distinguished academic researchers and leaders of health science companies, who will meet annually to review and guide the institute's scientific and financial operations.

Chairing the group will be Ronnie Cresswell, who formerly was a senior vice president of Warner Lambert Co. and the chairman of Parke-Davis Pharmaceutical Research in Ann Arbor.

"The Life Sciences Institute is a bold step forward by the University of Michigan," Cresswell says. "It's exciting for me to help lead this effort to blaze a new trail in biomedical research. We've assembled a really stellar group of advisors, and I'm looking forward to working with them on this vital project."

Alan Saltiel, director of LSI, also is looking forward to working with the advisory board. "We've recruited a spectacular group of advisors. I am excited that each has agreed to lend their expertise to our venture. They will keep us focused on the forefront of science and insure that we remain connected to the broader community in both the public and private sector."

External Advisory Board

Ronnie Cresswell, chair

Dr. Keith Black*, director, Maxine Dunitz Neurosurgical Institute and Division of Neurosurgery, Cedars Sinai Medical Center, Los Angeles

Sir William Castell, chief executive, Amersham plc, Buckinghamshire, U.K., who was knighted by Queen Elizabeth II in 2000 for his services to the life sciences industry

Dr. Peter B. Corr, senior vice president, Science and Technology, Pfizer Inc. Global Research and Development, New London, Conn.

Dr. Pedro Cuatrecasas, retired president, Parke Davis/Warner Lambert Pharmaceutical Research Division. A former National Institutes of Health researcher and currently professor of pharmacology and medicine at the University of California, San Diego

Jack E. Dixon, dean for scientific affairs, University of California, San Diego

Jennifer A. Doudna, Howard Hughes Medical Institute investigator and professor of molecular and cell biology, University of California, Berkeley

Dr. Richard P. Lifton,Howard Hughes Medical Institute investigator and Sterling Professor of Genetics and Internal Medicine, Yale University School of Medicine

Harvey F. Lodish, Whitehead Institute member, professor of biology and bioengineering, Massachusetts Institute of Technology

• Paul M. Meister*, vice chairman, Fisher Scientific International Inc., Hampton, N.H.

• Randy W. Schekman, Howard Hughes Medical Institute investigator, professor of molecular and cell biology, University of California, Berkeley

Christopher T. Walsh, Hamilton Kuhn Professor of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston

B. Joseph White*, managing director, Fred Alger Management Co., New York. Formerly U-M professor of Business Administration, dean of the Business School and interim president of the University

Dr. Tadataka Yamada, chairman, research and development, GlaxoSmithKline, King of Prussia, Penn.

* Denotes U-M alumni

More stories